Cover Image
市場調查報告書

Nociceptin受體:開發平台分析

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 358352
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
Nociceptin受體:開發平台分析 Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 50 Pages
簡介

本報告提供Nociceptin受體的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃相關資訊,以及最近的新聞和發表等訊息。

簡介

  • 調查範圍

Nociceptin受體概要

治療藥的開發

  • Nociceptin受體:開發中的產品 - 各開發階段
  • Nociceptin受體:開發中的產品 - 各治療範圍
  • Nociceptin受體開發中的產品 - 各適應症

Nociceptin受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Nociceptin受體:企業開發中的產品

Nociceptin受體:大學/機關開發中的產品

Nociceptin受體:治療藥的評估

  • 單劑療法/聯合治療產品的評估
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Nociceptin受體的治療藥開發企業

  • Astraea Therapeutics, LLC
  • F. Hoffmann-La Roche Ltd.
  • Grunenthal GmbH
  • Serodus ASA

Nociceptin受體的藥物簡介

Nociceptin受體:暫停中的計劃

Nociceptin受體:暫停中的計劃

Nociceptin受體:開發中止的產品

Nociceptin受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0519TDB

Summary

Global Markets Direct's, 'Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016', provides in depth analysis on Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted pipeline therapeutics.

The report provides comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • The report reviews Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Overview
  • Therapeutics Development
    • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Stage of Development
    • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Therapy Area
    • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Indication
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Companies
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Products under Development by Universities/Institutes
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Companies Involved in Therapeutics Development
    • Astraea Therapeutics, LLC
    • Grunenthal GmbH
    • Serodus ASA
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Drug Profiles
    • AT-076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-326 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cebranopadol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRTTA-2210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides to Agonize ORL1 for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-656570 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SER-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize NOP for Pain and Alcohol Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Dormant Projects
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Discontinued Products
  • Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Featured News & Press Releases
    • May 23, 2016: Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Potential and a Favorable Respiratory Profile
    • Apr 18, 2016: PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension
    • Feb 29, 2016: Cebranopadol Top-Line Data From Phase IIb Trial in Chronic Lower Back Pain Demonstrate Clinically and Statistically Significant Improvements in Pain Across All Arms
    • Apr 20, 2015: Provisional patent application filed for the Orphan Diseases of Pulmonary Hypertension
    • Sep 15, 2014: Serodus announces details on the clinical study of SER100 in patients with systolic hypertension
    • Sep 09, 2014: Serodus Announces Positive Phase IIa Clinical Study Results On SER100 In Patients with Systolic Hypertension
    • Jun 23, 2014: Serodus Completes The Enrollment Of Patients In Phase IIa Study
    • Nov 05, 2013: Serodus Enrolls First Patient in SER100 Phase IIa Isolated Systolic Hypertension Clinical Study
    • Apr 03, 2013: Serodus Receives Notice Of Allowance For Canadian Patent Covering SER100
    • Jan 11, 2011: Serodus Receives Patent For SER100 In Japan
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Astraea Therapeutics, LLC, H2 2016
  • Pipeline by Grunenthal GmbH, H2 2016
  • Pipeline by Serodus ASA, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top